We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Hologic and Agfa Finalize Development/Purchase Agreement

By HospiMedica staff writers
Posted on 24 Mar 2003
Following a joint development and OEM (original equipment manufacturer) purchase agreement in April 2002, Hologic, Inc. (Beford, MA, USA) and Agfa-Gevaert Group (Mortsel, Belgium) have now announced the final terms of that agreement.

Under these terms, Hologic will manufacture for Agfa, under the private label "Embrace,” a digital mammography system for distribution to specific international markets. The system will utilize Hologic's patented direct-to-digital amorphous selenium technology, which will be combined with Agfa's portfolio of image and information management systems. A leading imaging company, Agfa is active in 40 countries and has 120 agents throughout the world.

"Finalizing this agreement with Agfa-Gevaert moves us one step closer to making our direct capture digital mammography technology widely available on a global basis to healthcare providers and the women they serve,” said Jack Cummings, chairman and CEO of Hologic. The company's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to-digital x-ray for general radiography, and mini C-arm for orthopedic applications.




Related Links:
Hologic
Agfa
Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Absorbable Monofilament Mesh
Phasix Mesh

Channels

Critical Care

view channel
Image: Preprocessing, building, and applying multimodal AI in cardiology (Xin-yue Yang et al., Precision Clinical Medicine (2025). DOI: 10.1093/pcmedi/pbaf016)

Multimodal AI to Revolutionize Cardiovascular Disease Diagnosis and Treatment

Cardiovascular diseases remain the leading cause of death worldwide, and while artificial intelligence (AI) has shown promise in their diagnosis and management, most existing systems rely on a single data... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more